Latest Breaking News On - Pierre fabre - Page 2 : vimarsana.com

Idorsia announces changes to Idorsia Executive Committee

Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to.

United statesSan franciscoSwitzerland generalFrance generalAlberto gimonaArno groenewoudAndrewc weissJulien ganderJean paul clozelFelix ehratMathieu simonSandy mahatmePeter kelloggSrishti guptaMartine clozelBart filius

GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors

GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoFrance generalSwitzerland generalBart filiusJulien ganderAlberto gimonaPierre fabreArno groenewoudMartine clozelAndrewc weissSrishti guptaFelix ehratJean paul clozelPeter kelloggSandy mahatme

Idorsia Pharmaceuticals Ltd: Idorsia announces changes to Idorsia Executive Committee and Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board - taking

San franciscoUnited statesFrance generalSwitzerland generalSandy mahatmeMartine clozelAlberto gimonaBart filiusMathieu simonAndrewc weissArno groenewoudJean paul clozelPeter kelloggSophie kornowskiSrishti guptaFelix ehrat

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U S FDA

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20.

United statesPascal touchonPierre fabreSecurities exchangeMemorial sloan kettering cancer centerAtara biotherapeutics incExchange commissionDrug administrationBiologics license applicationChief executive officerObjective response rateSecurities actSecurities exchange actPierre fabre laboratoriesMiddle eastSouthern california

Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U S FDA

CASTRES, France, May 20, 2024 /PRNewswire/ Pierre Fabre Laboratories today announce the submission by Atara Biotherapeutics (ATARA), a leader in T-cell

United statesMidi pyréesPierre fabreAdriana herreraLaurence marchalPierre fabre pharmaceuticals incDrug administrationFirst allogeneict cell therapyTab cel wouldFirst approved therapyPierre fabre pharmaceuticalsPierre fabre laboratoriesBiologics license applicationChief executive officerPierre fabre medical careLaboratories media contact